OD-doxy-PNV-COVID-19 Old Drug " DOXY " for Prevention of New Virus " COVID-19 "

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Given the urgency of having guidelines for the management of COVID-19 in the current epidemic context and the lack of specific pharmacological treatment, Military Health recommends the launch of a multicenter, randomized, double-blind, interventional clinical trial.

The aim of this study is to evaluate the efficacy of a combination of two treatments, low-dose doxcycline (100 mg/day) and Zinc (15 mg/day) (dietary supplement) in the primary prevention of COVID-19 infection in health care professionals in Tunisia compared to two control groups.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hedi Gharsallah
• Collaborator: Dacima Consulting
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• No self-medication with study drugs or antivirals

• Negative COVID19 diagnosis confirmed by PCR and negative Elisa antibody assay

• No signs of COVID19

• Having given consent for the study

Exclusion Criteria:

Participation in other clinical trials aimed at primary prevention of VIDOC infection19

• Liver failure

• Known allergy to the study product

• Pregnancy or breastfeeding

• Vitamin A and E treatment in progress